| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.hester.in | |
| Market Cap | 1,866.32 Cr. | |
| Enterprise Value(EV) | 2,047.27 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 46.22 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 47.05 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 28.15 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 305.62 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 7.12 | Calculated using Price: 2,174.60 |
| Dividend Yield | 0.46 | Period Ending 2021-03 |
| No. of Shares Subscribed | 0.85 Cr. | 8,506,865 Shares |
| FaceValue | 10 | |
| Company Profile | ||
|
Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008. The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines. Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation. Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes – A, B & C. Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds. Hester currently manufactures 39 types of poultry vaccines against various poultry diseases. Product range of the company includes:
Achievements/ recognition:
|
||
Company Profile
Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.
The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.
Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.
Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes – A, B & C.
Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.
Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.
Product range of the company includes:
Achievements/ recognition:
| 1 Day |
|
+0.23% |
| 1 Week |
|
-4.50% |
| 1 Month |
|
-16.85% |
| 3 Month |
|
-1.99% |
| 6 Month |
|
-4.66% |
| 1 Year |
|
-19.98% |
| 2 Year |
|
+91.17% |
| 5 Year |
|
+157.06% |
| 10 Year |
|
+2410.22% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | 14.28 | 12.88 | 16.73 | 20.56 | 20.38 | 17.57 | 25.59 | 16.38 | 16.16 | |
| Return on Capital Employed (%) | 20.10 | 17.78 | 17.26 | 18.98 | 19.75 | 20.20 | 26.64 | 16.53 | 17.33 | |
| Return on Assets (%) | 8.28 | 6.89 | 8.84 | 11.08 | 11.43 | 10.10 | 14.97 | 9.04 | 8.70 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 67 | 75 | 85 | 102 | 122 | 141 | 177 | 201 | 228 | 260 | |
| Non Curr. Liab. | 16 | 20 | 38 | 41 | 48 | 44 | 70 | 97 | 114 | 198 | |
| Curr. Liab. | 39 | 45 | 35 | 38 | 38 | 55 | 49 | 83 | 61 | 97 | |
| Minority Int. | 1 | 1 | 3 | 5 | 5 | 4 | 4 | 5 | 8 | 7 | |
| Equity & Liab. | 124 | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 | |
| Non Curr. Assets | 74 | 85 | 100 | 112 | 133 | 146 | 158 | 227 | 250 | 367 | |
| Curr. Assets | 50 | 57 | 60 | 74 | 80 | 98 | 142 | 159 | 162 | 195 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 124 | 142 | 160 | 186 | 213 | 244 | 299 | 387 | 411 | 562 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 65 | 69 | 90 | 101 | 123 | 136 | 178 | 183 | 214 | 235 | |
| Other Income | 0 | 1 | 0 | 1 | 0 | 3 | 7 | 6 | 5 | 14 | |
| Total Income | 65 | 70 | 90 | 102 | 124 | 138 | 185 | 190 | 219 | 249 | |
| Total Expenditure | -43 | -45 | -65 | -68 | -82 | -89 | -110 | -128 | -146 | -175 | |
| PBIDT | 22 | 25 | 26 | 34 | 41 | 50 | 75 | 62 | 73 | 74 | |
| Interest | -3 | -6 | -5 | -4 | -4 | -4 | -7 | -7 | -7 | -4 | |
| Depreciation | -4 | -5 | -6 | -6 | -7 | -10 | -12 | -13 | -13 | -17 | |
| Taxation | -5 | -4 | -5 | -6 | -8 | -13 | -16 | -10 | -15 | -14 | |
| Exceptional Items | 3 | -3 | |||||||||
| PAT | 9 | 9 | 13 | 19 | 23 | 23 | 41 | 31 | 35 | 39 | |
| Minority Interest | 0 | 0 | 0 | 0 | 1 | 3 | 1 | -2 | 0 | 0 | |
| Share Associate | 0 | ||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 9 | 9 | 14 | 19 | 24 | 26 | 42 | 29 | 34 | 39 | |
| Adjusted EPS | 11 | 11 | 16 | 23 | 28 | 30 | 49 | 34 | 40 | 46 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 14 | 12 | 9 | 20 | 19 | 35 | 38 | 47 | 37 | 58 | |
| Cash Fr. Inv. | -10 | -23 | -15 | -21 | -13 | -30 | -26 | -22 | -74 | -38 | |
| Cash Fr. Finan. | -2 | 10 | 7 | 7 | -7 | 2 | -11 | 3 | 19 | -18 | |
| Net Change | 2 | -1 | 2 | 5 | -1 | 6 | 1 | 28 | -19 | 1 | |
| Cash & Cash Eqvt | 3 | 2 | 4 | 6 | 5 | 11 | 12 | 41 | 24 | 21 |
|
Thu, 26 May 2022
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Submission of earnings conference call held on Friday 20 May 2022 to discuss the standalone and consolidated audited financial results for the quarter and year ended 31 March 2022. |
|
Mon, 23 May 2022
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) this is to inform you that we are in receipt of intimation from the shareholder regarding loss of share certificate(s). |
|
Mon, 23 May 2022
Compliances-Reg.24(A)-Annual Secretarial Compliance Annual Secretarial Compliance Report of the Company for the year ended 31 March 2022 |
| Fri, 27 May 2022 |
Closing Above Previous High
|
Making Lower Lows for 3 days
|
Close Within 52 Week Low Zone
|
High Decrease 1 Month
|
High Increase 2 Years
|
Equities
M.F.
Sectors